TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Impedimed Limited ( (AU:IPD) ) has issued an announcement.
ImpediMed Limited announced a change in the director’s interest, with Ms. Christine Emmanuel-Donnelly acquiring additional ordinary shares through IDEAHL Pty Ltd. The acquisition was made in lieu of 15% of director fees for the quarter ended 30 September 2025, reflecting a strategic move to align director compensation with company performance. This change in shareholding may impact the company’s governance and stakeholder confidence by demonstrating the director’s commitment to the company’s growth and success.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited operates in the medical technology industry, focusing on the development and sale of bioimpedance spectroscopy devices. These devices are primarily used for the non-invasive assessment of body composition and fluid status, with applications in healthcare sectors such as oncology, cardiology, and renal care.
Average Trading Volume: 1,808,782
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$77.37M
See more data about IPD stock on TipRanks’ Stock Analysis page.